Targeting a specific protein to treat chronic myeloid leukemia

Who could benefit from this research

What this research studies

This research focuses on developing a small protein that can inhibit the dimerization of Bcr-Abl, a protein responsible for the majority of chronic myeloid leukemia cases. By preventing Bcr-Abl from dimerizing, the treatment aims to disrupt its oncogenic activity, which is crucial for the progression of the disease. The approach involves using a computationally designed coiled-coil mutant that selectively interacts with Bcr-Abl, potentially offering a new therapeutic strategy. Patients may benefit from this innovative treatment if it proves effective in clinical settings.

Why it matters

Where this research is happening

• University of Utah
  Salt Lake City, United States Active

Researchers

• Principal investigator: Lim, Carol S. — University of Utah
• Study coordinator: Lim, Carol S.

Related research

Other NIH-funded projects on the same topics.

• Chronic myeloid leukemia: how T cells and leukemia stem cells interact during treatment

  This NIH grant explores how immune cells and stubborn leukemia stem cells interact during therapy to better predict if patients can stay off treatment.

  NIH research Northwestern University · Chicago, United States · NIH-11418370

• Targeting DYRK2 to kill leukemia stem cells in CML

  Aims to find ways to remove leukemia stem cells in chronic myeloid leukemia by boosting a protein (DYRK2) that can halt their growth.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11323889

• Why chronic myeloid leukemia sometimes resists treatment and how to improve TKI care

  This project looks at why some people with chronic myeloid leukemia respond differently to tyrosine kinase inhibitor drugs and aims to help more patients get deeper, longer-lasting remissions.

  NIH research University of California-Irvine · Irvine, United States · NIH-11306059

• Targeting a specific protein to eliminate leukemia stem cells in chronic myeloid leukemia.

  This study is looking at a new way to help people with chronic myeloid leukemia (CML) by focusing on a protein called DYRK2, which could help make leukemia stem cells less likely to survive, so patients might be able to stop their current treatments without their cancer coming back.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11109689

• Understanding how some patients with chronic myeloid leukemia can remain healthy without treatment

  This study is looking into why some people with chronic myeloid leukemia can stay healthy without taking their medication, using mice to find out what helps them maintain remission, which could lead to better ways to manage the condition and lessen the need for long-term treatment.

  NIH research University of California-Irvine · Irvine, United States · NIH-11078332

• Improving treatment for chronic myeloid leukemia with targeted therapies

  This study is looking for ways to help people with chronic myeloid leukemia (CML) respond better to their main treatment, tyrosine kinase inhibitors (TKIs), especially during the first year after they are diagnosed, so that more patients can achieve a lasting remission and possibly a cure.

  NIH research University of California-Irvine · Irvine, United States · NIH-11016818

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.